SEC Comment Letter for Theriva Biologics, Inc. (TOVX) (CIK 0000894158) (TOVX) — Sep 20, 2017
Theriva Biologics, Inc. (TOVX) (CIK 0000894158)
Date: Sept. 20, 2017 · CIK: 0000894158 · Accession: 0000000000-17-033371
AI Filing Summary & Sentiment
Reasoning
Letter
September 20, 2017 Steven A. Shallcross Chief Financial Officer Synthetic Biologics, Inc. 9605 Medical Center Drive, Ste. 270 Rockville, MD 20850 Synthetic Biologics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2016 Filed March 2, 2017 File No. 001-12584Re: Dear Mr. Shallcross: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence by the staff. Division of Corporation Finance Office of Healthcare & Insurance cc: Leslie Marlow, Esq. - Gracin & Marlow, LLP
Show Raw Text
September 20, 2017 Steven A. Shallcross Chief Financial Officer Synthetic Biologics, Inc. 9605 Medical Center Drive, Ste. 270 Rockville, MD 20850 Synthetic Biologics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2016 Filed March 2, 2017 File No. 001-12584Re: Dear Mr. Shallcross: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence by the staff. Division of Corporation Finance Office of Healthcare & Insurance cc: Leslie Marlow, Esq. - Gracin & Marlow, LLP